Levotiz-A Tablet SR is a sustained-release formulation combining Ambroxol (75mg), Levocetirizine (5mg), and Montelukast (10mg), designed for the comprehensive management of respiratory conditions characterized by inflammation, allergic responses, and mucus hypersecretion. Ambroxol, a mucolytic agent, facilitates the breakdown and clearance of thick mucus from the respiratory tract, enhancing expectoration and improving airway patency. Levocetirizine, a potent second-generation antihistamine, effectively alleviates symptoms of allergic rhinitis and urticaria by selectively inhibiting peripheral H1 receptors, thereby reducing histamine-induced inflammation, itching, and nasal congestion without causing significant sedation. Montelukast, a leukotriene receptor antagonist, targets leukotriene-mediated bronchoconstriction and inflammation, contributing to improved airway function and symptom control in conditions such as asthma and allergic rhinitis. The sustained-release formulation ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. Levotiz-A Tablet SR is indicated for patients requiring multi-modal treatment of chronic respiratory allergies, asthma, and associated mucus hypersecretion. It should be used under medical supervision, considering potential contraindications and drug interactions. Adverse effects are generally mild but may include gastrointestinal disturbances, headache, and drowsiness. Regular monitoring and adherence to prescribed dosage are essential for optimal therapeutic outcomes.